Skip to main content
NewslettersWatchlist

Blueprint Medicines Corp(BPMC-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low129.30
Day High129.55
Open:129.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Blueprint Medicines Corp

Select a category then submit the form to load news
Business Wire
Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction
Business Wire
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
Tipranks
Blueprint Medicines Completes $9.1B Merger, Delists from Nasdaq
Tipranks
Blueprint Medicines (BPMC) Gets a Hold from Barclays
Tipranks
Barclays Sticks to Their Hold Rating for Blueprint Medicines (BPMC)
Tipranks
UBS Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
Tipranks
Leerink Partners Sticks to Their Hold Rating for Blueprint Medicines (BPMC)
Tipranks
Robert W. Baird Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), Blueprint Medicines (BPMC) and Vera Therapeutics (VERA)
Tipranks
Blueprint Medicines (BPMC) was downgraded to a Hold Rating at TD Cowen
Tipranks
Citi Sticks to Its Sell Rating for Blueprint Medicines (BPMC)
Tipranks
Needham downgrades Blueprint Medicines (BPMC) to a Hold
Tipranks
M&A News: Sanofi Expands Cancer Drug Portfolio with $9.1B Blueprint Medicines Acquisition
SYNDTGAM
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion
French drugmaker Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago.
Barchart
Stocks Set to Open Lower as Trade Tensions Flare, U.S. Jobs Data and Powell Speech Awaited
Down day candlestick chart by Bigc Studio via Shutterstock
Yolowire
Blueprint Medicines Is A Fast-Growing Small-Cap Stock
Tipranks
Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Envista Holdings (NVST) and Hologic (HOLX)
Tipranks
Scotiabank Keeps Their Buy Rating on Blueprint Medicines (BPMC)
Tipranks
Analysts Conflicted on These Healthcare Names: Teleflex (TFX) and Blueprint Medicines (BPMC)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), Teleflex (TFX) and Blueprint Medicines (BPMC)
Tipranks
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Blueprint Medicines (BPMC) and Ionis Pharmaceuticals (IONS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC)
Tipranks
Blueprint Medicines (BPMC) Receives a Buy from Wedbush
Tipranks
Piper Sandler Remains a Hold on Blueprint Medicines (BPMC)
Barchart
Chart of the Day: Does Blueprint Medicines Have a Blueprint for Success?
BPMC
Motley Fool
Why Blueprint Medicines Stock Soared Today
PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Motley Fool
Why Shares of Blueprint Medicines Are Falling Wednesday
PR Newswire
Blueprint Medicines Reports Second Quarter 2023 Results
PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Profile

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.